Cantor Fitzgerald reiterates Neutral rating on Merck stock at $120

Cantor Fitzgerald maintained a Neutral rating and $120 price target on Merck despite the stock trading at $149.50, near its $156.92 52-week high, following substantial optimism around intismeran's melanoma data. The upcoming ESMO presentation for the INTerpath-001 adjuvant-melanoma study, stopped early for overwhelming efficacy, will center on its recurrence-free-survival hazard ratio, with market expectations at 0.60-0.65. Analyst views remain divided: price targets range from $120 to $180, while bullish estimates project intismeran peak sales of $7 billion to $16 billion.

Analysis

MRK’s rerating now embeds a meaningful probability that its individualized neoantigen platform becomes a durable post-Keytruda franchise rather than a single melanoma opportunity. The key issue is not whether recurrence-free survival is statistically positive, but whether the hazard ratio and safety profile support use in lower-risk, larger adjuvant populations; a result near the optimistic end of expectations could justify oncology pipeline value, while a result nearer 0.65 likely leaves limited upside after the recent market-cap expansion. Because MRK shares economics with MRNA, the latter has materially greater equity sensitivity to a positive readout despite being less frequently framed as the primary beneficiary.

Over the next days-to-weeks, ESMO detail is the catalyst, but the more investable 1-3 month question is whether clinicians view the data as sufficient to support enrollment, reimbursement, and label-expansion confidence across tumor types. MRK faces asymmetric downside if durability, subgroup consistency, or treatment discontinuations disappoint: its valuation leaves less room for a “good but not transformational” outcome, while MRNA’s platform optionality can be repriced sharply in either direction. The 6-18 month structural risk is manufacturing complexity and commercial scalability of individualized vaccines; impressive efficacy does not automatically translate into broad margins if turnaround time or site logistics constrain adoption.

Consensus appears too focused on peak-sales estimates and insufficiently on ownership of upside. MRK has the commercialization infrastructure, but MRNA has a smaller base business and a more convex valuation response to validation of its oncology platform. Conversely, MRNA’s higher beta makes it vulnerable if the presentation merely confirms expectations rather than materially improving confidence in broad tumor applicability.

Key Decisions for Investors

• Prefer a catalyst pair: long MRNA / short MRK in risk-adjusted equal dollar size into ESMO, held through data and reassessed within 48 hours. This isolates shared-program upside while favoring the more operationally leveraged equity; use a 10-12% MRNA stop or reduce exposure if disclosed efficacy is no better than the market’s roughly 0.60-0.65 hazard-ratio expectation.
• For MRK-only exposure, avoid chasing spot near recent highs; initiate only if post-presentation data demonstrate durable benefit, clean tolerability, and credible expansion beyond melanoma. A 5-8% pullback following merely in-line data would be a more attractive entry, whereas a guidance or pipeline-value reset would invalidate the near-term long thesis.
• Use MRNA call spreads rather than outright calls if implied volatility rises materially into the event: buy 3-6 month upside exposure and sell a higher strike to limit event-volatility decay. The trade requires confirmation of option implied volatility and event timing before execution.
• Monitor subsequent management commentary on manufacturing turnaround time, per-patient gross margin, and trial starts in additional tumors. Failure to show scalable operations within the next two quarters would weaken the long-duration thesis even if melanoma efficacy remains compelling.